Market research reports, consulting: Global Market Insights Inc.

Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > hypoparathyroidism treatment market

Hypoparathyroidism Treatment Market Trends

Report ID: GMI8302 Published Date: February 2024Report Format: PDF
Download Free Sample
Summary
Table of Content

Hypoparathyroidism Treatment Market Trends

  • Increasing incidence of hypoparathyroidism is a significant driving factor. The prevalence of hypoparathyroidism is an estimated 37 per 100 000 person-years in the U.S. Additionally, it is estimated that approximately 7.6% of all thyroid related surgeries result in hypoparathyroidism.
  • Thus, as the number of cases increases, the demand for treatment also rises, thereby driving the market growth.
  • Further, growing awareness about parathyroid disorders, their symptoms, and potential complications has led to an increased number of patients seeking medical advice and treatment. This awareness results in a higher number of diagnosed cases and, consequently, a greater demand for hypoparathyroidism treatments.

However, the high cost of treatment can impose a significant financial burden on patients and their families. Consequently, due to financial constraints, some individuals delay seeking medical attention or avoid necessary tests and treatments for hypoparathyroidism, thereby impeding market growth to some extent.

Author: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :

Which companies define the competitive landscape of global hypoparathyroidism treatment industry?+

Ascendis Pharma A/S, Amgen Inc., BioNTech SE, Bristol-Myers Squibb Company, Entera Bio Ltd., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., SK biopharmaceuticals Co., Ltd., Sun Pharmaceutical Industries Ltd. are some of the major industry contenders.

What factors are pushing the growth of North America hypoparathyroidism treatment market?+

North America market for hypoparathyroidism treatment is expected to grow at 6.8% rate during 2024 and 2032, driven by the presence of advanced healthcare infrastructure with access to state-of-the-art medical facilities and specialized healthcare professionals.

Why is the demand for supplements in hypoparathyroidism treatment industry increasing?+

The supplements segment garnered USD 888.2 million in 2023 and is set to gain traction by 2032, attributed to the well-established safety profile of supplements, and ease of availability.

How big is the hypoparathyroidism treatment market?+

The market size for hypoparathyroidism treatment was valued at USD 1.3 billion in 2023 and is estimated to account for USD 2.4 billion by 2032, driven by the increasing cases of hypo parathyroid disorders and rising number of thoracic surgeries.

Hypoparathyroidism Treatment Market Scope

Related Reports

Buy Now

Buy Now

Premium Report Details

Download Free Sample